USFDA inspects Shilpa Medicare’s bio-analytical laboratory in Hyderabad
Drug Approval

USFDA inspects Shilpa Medicare’s bio-analytical laboratory in Hyderabad

This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently

  • By IPP Bureau | March 02, 2024

The Bio Analytical Laboratory, Shilpa Medicare Limited, Unit 7, Nacharam, Hyderabad, India was inspected by USFDA from Feb 26, 2024 to March 1, 2024.

This unannounced USFDA Inspection has been closed without any 483 observation, stating the satisfactory compliance towards facility, systems and acceptability of data generated from this laboratory.

This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently and this is the first USFDA inspection.

This Unit of Shilpa Medicare is engaged in testing of biological samples that supports all exploratory pharmacokinetic studies, bioavailability studies and bioequivalence studies, while complying with good clinical practices and good laboratory practices as per the global regulatory standards.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International